PMGC Holdings Inc. (ELAB) - 10-Q Summary for Period Ended September 30, 2025
Business Context and Reporting Period
This Quarterly Report covers the period ended September 30, 2025. PMGC Holdings Inc. (formerly Elevai Labs Inc.) has transitioned from a skincare development company to a diversified holding company following the sale of its skincare business on January 16, 2025. The company now operates through five wholly owned subsidiaries focusing on biopharmaceuticals, investment management, IT packaging, and precision engineering. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Balance Sheet (Sept 30, 2025) |
|---|---|---|---|
| Revenue | $285,948 | $285,948 | - |
| Gross Profit | $78,030 | $78,030 | - |
| Gross Margin | 27.3% | 27.3% | - |
| Net Loss (Continuing Ops) | $(2,616,018) | $(4,776,319) | - |
| Total Net Loss | $(2,594,320) | $(4,765,130) | - |
| Cash and Equivalents | - | - | $7,700,562 |
| Working Capital | - | - | $4,310,939 |
| Convertible Debt | - | - | $3,194,053 |
| Derivative Liabilities | - | - | $681,818 |
Material Changes vs. Prior Period
- Revenue Generation: Revenue increased from $0 in the prior year periods to $285,948, driven entirely by two acquisitions completed in Q3 2025: Pacific Sun Packaging Inc. (IT packaging) and AGA Precision Systems LLC (CNC machining).
- Operating Expenses: Total operating expenses for the nine months ended Sept 30, 2025, were $4,492,173, a significant increase from $1,981,831 in the prior year. This was driven by higher consulting fees ($1.37M vs $0.78M), professional fees ($0.94M vs $0.27M), and new repair/maintenance costs ($0.31M) related to acquired assets.
- Discontinued Operations: The skincare business, previously a major operational segment, was sold in January 2025. Results are now reported as discontinued operations, showing a net loss of $2,012,113 for the nine months ended Sept 30, 2024, compared to a net income of $11,189 for the same period in 2025.
- Investment Activity: The company recorded a realized loss on investments of $397,365 and an unrealized loss of $230,461 in the current quarter, contrasting with gains in the prior year.
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states that the company's accumulated deficit ($18.0M) and net losses raise substantial doubt about its ability to continue as a going concern. Continuation depends on obtaining necessary equity financing and acquiring cash-flow-generating assets.
- Capital Strategy: Management plans to raise additional debt or equity financing. In September 2025, the company established a $20M Equity Line of Credit (ELOC) and consummated a $5M pre-paid purchase, resulting in $3.99M in net cash proceeds.
- Strategic Focus: Future plans include advancing clinical development for NorthStrive Biosciences (EL-22 asset), pursuing acquisitions of B2B companies with positive EBITDA, and utilizing PMGC Capital for direct investments.
- Risks: Key risks include the inability to raise sufficient funds, dependency on key personnel, potential impairment of goodwill from recent acquisitions, and the volatility of investment securities.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure further financing given the explicit "substantial doubt" disclosure and high burn rate.
- Acquisition Integration: Assess the preliminary purchase price allocations for Pacific Sun and AGA Precision Systems, specifically the valuation of goodwill ($959,535 total) and intangible assets.
- Debt Structure: Review the terms of the new $5M convertible debt and the embedded derivative liability ($681,818), noting the conversion floor price of $1.058 per share.
- Related Party Transactions: Scrutinize the $1.37M in consulting fees, a significant portion of which ($616,800) relates to contractual bonuses for the CEO, CFO, and Chairman.
- Stock Splits: Confirm share counts are adjusted for the cumulative 1-for-4,900 reverse stock split effective through September 2025.